“Such findings underscore the need for and importance of molecular testing to inform management along with continued research to establish treatment paradigms with appropriately targeted therapies for patients with prostate cancer,” the authors wrote.

The approval of the first PARP inhibitors for prostate cancer was hailed as the “dawn of the precision medicine era” in the field.

“I think as our understanding of mutations [and] our understanding the PARP inhibitors [grows], if the data pans out, we’ll be using these earlier and earlier in patients, which I think we’ll [will allow us to] see probably more benefit,” says Jason M. Hafron, MD.

“Some potential…combination therapy may be valuable, such as combining with a checkpoint inhibitor or some target senescence because this resistance involves those kinds of mechanisms,” says Allen C. Gao, MD, PhD.